NEW YORK, Oct. 22, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or the “Company”). HGEN and some of his officers. The class action, filed in the United States District Court for the District of New Jersey and registered at 22-cv-05258, is on behalf of a class consisting of all persons and entities other than the defendants who purchased or otherwise acquired Humanigen securities May 28, 2021 and July 12, 2022, both dates inclusive (the “Collection Period”), in an attempt to recover damages caused by Defendants’ violations of the federal securities laws and to seek remedies under Sections 10(b ) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against the Company and certain of its senior officials.
If you are a shareholder who purchased or otherwise acquired Humanigen securities during the class action period, you have until October 25, 2022 to ask the court to appoint you as lead plaintiff in the class action. A copy of the complaint is available at www.pomerantzlaw.com. To discuss this promotion, contact Robert S. Willoughby at newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, ext. 7980. Individuals inquiring by email are asked to provide their mailing address, telephone number and the number of shares purchased.
[Click here for information about joining the class action]
Humanigen is a clinical-stage biopharmaceutical company focused on the prevention and treatment of an immune system overreaction called “cytokine storm,” a physiological response in which the immune system suddenly causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines in large amounts can cause multisystem organ failure and death. The company’s lead product candidate is its proprietary antibody lenzilumab, which is…
